Prosecution Insights
Last updated: August 15, 2026

Akouos, Inc.

6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
4
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (1)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (50%)
2
Medium (33%)
1
Easy (17%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (17%)
§112 only1 (17%)
Double-patenting + other2 (33%)
Multi-statute (no §101)2 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SINGH, ANOOP KUMAR 2 42.8% +67.4%
PRONZATI, GINA 1 65.7% +45.2%
CHONG, KIMBERLY 1 72.4% +12.8%
VIVLEMORE, TRACY ANN 1 73.0% +6.7%
ARIETI, RUTH SOPHIA 1 45.3% +72.1%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18314671 CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS PRONZATI, GINA 32d overdue
19095919 ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS SINGH, ANOOP KUMAR
17923636 COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS VIVLEMORE, TRACY ANN

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18314671 CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS PRONZATI, GINA 32d overdue
18314661 CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS CHONG, KIMBERLY 13d
19095986 ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS SINGH, ANOOP KUMAR 28d
19095919 ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS SINGH, ANOOP KUMAR
17253658 METHODS OF TREATING CLRN1-ASSOCIATED HEARING LOSS AND/OR VISION LOSS ARIETI, RUTH SOPHIA

Top Art Units

Art UnitApps
1632 2
1633 1
1636 1
1638 1
1635 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19095986 ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS SINGH, ANOOP KUMAR 1632 §103§112DP Final Rejection 28d Pending Mar 31, 2025
19095919 ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS SINGH, ANOOP KUMAR 1632 §103§112Other Non-Final OA Pending Mar 31, 2025
18314671 CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS PRONZATI, GINA 1633 §102§103Other Non-Final OA 32d overdue Pending May 09, 2023
18314661 CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS CHONG, KIMBERLY 1636 §112Other Non-Final OA 13d Pending May 09, 2023
17923636 COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS VIVLEMORE, TRACY ANN 1638 §101§103§112 Final Rejection Pending Nov 07, 2022
17253658 METHODS OF TREATING CLRN1-ASSOCIATED HEARING LOSS AND/OR VISION LOSS ARIETI, RUTH SOPHIA 1635 §112DP Non-Final OA Pending Dec 18, 2020

Managing Akouos, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month